ACTRIMS 2023 | Real-world use of the MSDA test: a case series

Ferhan Qureshi, VP – Biomarker Product Development, Octave, Menlo Park, CA, describes findings from a case series report on the real-world use of the proteomic Multiple Sclerosis Disease Activity (MSDA) test. The validated MSDA test was piloted in select centers and is now broadly available for routine clinical use. This report included the initial experience using the MSDA test in 5 patients at the Michigan Institute for Neurologic Disorders, Farmington Hills, MI, with diverse clinical presentations. The results demonstrate that disease activity scores appear to correlate with relapses and therapy efficacy, suggesting that the MSDA test can be used to verify stability and may support the clinical decision to alter therapy. This interview took place at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2023 in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.